1. Home
  2. SLRC vs LQDA Comparison

SLRC vs LQDA Comparison

Compare SLRC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLRC
  • LQDA
  • Stock Information
  • Founded
  • SLRC 2007
  • LQDA 2004
  • Country
  • SLRC United States
  • LQDA United States
  • Employees
  • SLRC N/A
  • LQDA N/A
  • Industry
  • SLRC Finance/Investors Services
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLRC Finance
  • LQDA Health Care
  • Exchange
  • SLRC Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • SLRC 885.4M
  • LQDA 957.2M
  • IPO Year
  • SLRC 2010
  • LQDA 2018
  • Fundamental
  • Price
  • SLRC $16.37
  • LQDA $11.80
  • Analyst Decision
  • SLRC Sell
  • LQDA Strong Buy
  • Analyst Count
  • SLRC 4
  • LQDA 8
  • Target Price
  • SLRC $15.25
  • LQDA $27.14
  • AVG Volume (30 Days)
  • SLRC 171.1K
  • LQDA 840.8K
  • Earning Date
  • SLRC 11-06-2024
  • LQDA 11-13-2024
  • Dividend Yield
  • SLRC 10.02%
  • LQDA N/A
  • EPS Growth
  • SLRC 34.99
  • LQDA N/A
  • EPS
  • SLRC 1.77
  • LQDA N/A
  • Revenue
  • SLRC $236,635,000.00
  • LQDA $15,610,000.00
  • Revenue This Year
  • SLRC $4.11
  • LQDA N/A
  • Revenue Next Year
  • SLRC N/A
  • LQDA $209.63
  • P/E Ratio
  • SLRC $9.23
  • LQDA N/A
  • Revenue Growth
  • SLRC 5.79
  • LQDA N/A
  • 52 Week Low
  • SLRC $14.41
  • LQDA $8.26
  • 52 Week High
  • SLRC $16.91
  • LQDA $16.99
  • Technical
  • Relative Strength Index (RSI)
  • SLRC 52.94
  • LQDA 62.12
  • Support Level
  • SLRC $15.79
  • LQDA $10.37
  • Resistance Level
  • SLRC $16.21
  • LQDA $11.44
  • Average True Range (ATR)
  • SLRC 0.24
  • LQDA 0.54
  • MACD
  • SLRC -0.07
  • LQDA 0.06
  • Stochastic Oscillator
  • SLRC 51.79
  • LQDA 92.86

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: